Daré Bioscience, Inc. (DARE)

Market Cap	25.84M
Revenue (ttm)	25,909
Net Income (ttm)	-1.68M
Shares Out	8.85M
EPS (ttm)	-0.20
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	56,124
Open	2.890
Previous Close	2.885
Day's Range	2.880 - 2.920
52-Week Range	2.670 - 5.760
Beta	1.20
Analysts	Strong Buy
Price Target	12.50 (+328.08%)
Earnings Date	Aug 11, 2025

About DARE

Daré Bioscience, Inc. develops therapies in the areas of contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States. The company offers XACIATO, a lincosamide antibacterial gel for the treatment of bacterial vaginosis. It also develops Ovaprene, a hormone-free monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia for the treatment of female sexual arousal disorder; DARE-HRT1 to treat vasomotor sympto...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Employees: 23
• Stock Exchange: NASDAQ
• Ticker Symbol: DARE
• Website: https://darebioscience.com

Financial Performance

In 2024, Daré Bioscience's revenue was $9,784, a decrease of -99.65% compared to the previous year's $2.81 million. Losses were -$4.05 million, -86.56% less than in 2023.

Analyst Forecast

According to 3 analysts, the average rating for DARE stock is "Strong Buy." The 12-month stock price forecast is $12.5, which is an increase of 328.08% from the latest price.

Price Target

$12.5

(328.08% upside)

Analyst Consensus: Strong Buy